ATAI vs TYRA
ATAI: A clinical-stage biotechnology company dedicated to developing innovative mental health therapies through a diverse pipeline of neuropsychiatric treatments. TYRA: Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly targeting FGFR-driven diseases.
Side-by-side fundamentals
| Metric | ATAI | TYRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.18 | $30.59 | |
| Market cap as of 2026-07-23 | $2.7B | $1.8B | |
| PEG as of 2026-07-23 | n/a | -0.44 | |
| Net margin as of 2026-07-23 | -19019.4% | n/a | |
| Operating margin as of 2026-07-23 | -18569.1% | n/a | |
| ROE as of 2026-07-23 | -366.5% | -42.7% | TYRA higher |
| ROA as of 2026-07-23 | -269.0% | -39.8% | TYRA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +86.7% | n/a | |
| Beta as of 2026-07-23 | 1.60 | 0.75 | |
| 1-year return as of 2026-07-22 close | +102.1% | +200.2% | TYRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.